Literature DB >> 6208354

Histamine H2 receptor desensitization in HL-60 human promyelocytic leukemia cells.

D G Sawutz, K Kalinyak, J A Whitsett, C L Johnson.   

Abstract

Recent studies have suggested that cyclic AMP (cAMP) may be involved in regulation of cell growth and differentiation of cancer cells. Incubating HL-60 cells in the presence of the specific H2 agonist dimaprit resulted in 30-fold increases in cAMP levels (EC50 = 5.7 X 10(-6) M) and morphological changes suggestive of cell maturation along the granulocyte pathway. However, cells cultured with 10(-5) M dimaprit showed more than an 80% decrease in their cAMP response to subsequent addition of H2 agonists, whereas the cAMP response to prostaglandin E2 was unaltered. Desensitization was time-dependent (halftime approximately 2.5 hr with 10(-5) M dimaprit), dose-dependent (dimaprit EC50 = 1.4 X 10(-6) M) and completely prevented by 10(-3) M cimetidine. Desensitization of HL-60 cells for 4 hr with 10(-5) M dimaprit followed by the addition of 10(-3) M cimetidine resulted in total recovery of the cAMP response in less than 24 hr. The pharmacologically inactive analog N-methyldimaprit (SK&F 92054) did not increase cAMP production or cause desensitization to H2 stimulation. Desensitization was observed in the presence or absence of a phosphodiesterase inhibitor, indicating that induction of cAMP-phosphodiesterase was not involved in this process. No difference in the number of [3H]tiotidine binding sites was observed between control and dimaprit-desensitized HL-60 cells. Based on these results, we suggest that H2 receptor agonists caused an agonist-dependent desensitization, presumably due to an uncoupling of receptors from adenylate cyclase.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6208354

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Stimulation of histamine H2- (and H1)-receptors activates Ca2+ influx in all-trans-retinoic acid-differentiated HL-60 cells independently of phospholipase C or adenylyl cyclase.

Authors:  R Burde; R Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-01       Impact factor: 3.000

2.  Flow cytometric analysis with a fluorescently labeled formyl peptide receptor ligand as a new method to study the pharmacological profile of the histamine H2 receptor.

Authors:  Kristin Werner; Solveig Kälble; Sabine Wolter; Erich H Schneider; Armin Buschauer; Detlef Neumann; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-05-30       Impact factor: 3.000

3.  Effects of histamine, granulocyte colony-stimulating factor and db-cAMP on the differentiation of HL-60 cells.

Authors:  K Tasaka; N Nakaya; T Nonaka
Journal:  Agents Actions       Date:  1990-04

4.  The growth capacity of hematopoietic progenitor cells in severe neutropenia induced by famotidine.

Authors:  T Liersch; J H Beyer; G Krieger; K Vehmeyer
Journal:  Ann Hematol       Date:  1992-05       Impact factor: 3.673

5.  A novel network pharmacology approach for leukaemia differentiation therapy using Mogrify®.

Authors:  Lin Ming Lee; Eleni G Christodoulou; Pavithra Shyamsunder; Bei Jun Chen; Kian Leong Lee; Tsz Kan Fung; Chi Wai Eric So; Gee Chuan Wong; Enrico Petretto; Owen J L Rackham; S Tiong Ong
Journal:  Oncogene       Date:  2022-10-21       Impact factor: 8.756

Review 6.  Molecular and cellular analysis of human histamine receptor subtypes.

Authors:  Roland Seifert; Andrea Strasser; Erich H Schneider; Detlef Neumann; Stefan Dove; Armin Buschauer
Journal:  Trends Pharmacol Sci       Date:  2012-12-17       Impact factor: 14.819

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.